However, its important to keep in mind that this is only an average, and results on semaglutide vary
Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication
A 2023 study by Azuri et al showed 17.8% total body weight loss for tirzepatide vs
Semaglutide is typically prescribed for adults with type 2 diabetes who need help managing their blood sugar levels
So is Zyas Sauer
In controlled lighting studies involving rodents subjected to constant illumination (a stressor that disrupts circadian patterns), intermittent Epithalon treatment normalized melatonin and cortisol rhythms, partially preserving typical daynight physiological cycles [2][4][5]
-1.jpg&w=1200&q=75)
